doi:https://doi.org/

References:

Morgan R.E., Campbell S.E., Suehira K., et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 2012;60:158—164.
Aberg J.A., Gallant J.E., Ghanem K.G., et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:e1—34.
Stender S., Budinski D., Gosho M., Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 2013;20:40—53.
Sponseller C.A., Morgan R.E., Kryzhanovski V.A., et al. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther 2014;36:1211—1222.
Myerson M., Malvestutto C., Aberg J.A. Management of lipid disorders in patients living with HIV. J Clin Pharmacol 2015;55:957—974.
Jacobson T.A., Maki K.C., Orringer C.E., et al, on behalf of the NLA Expert Panel. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 2015;9(suppl):S1—122. e1.
Kowa Pharmaceuticals America, Inc and Eli Lilly and Company. LIVALO [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc, and Indianapolis, IN: Eli Lilly and Company; October, 2013.
Malvestutto C.D., Ma Q., Morse G.D., Underberg J.A., Aberg J.A. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 2014;67:390—396.
Gerber J.G., Rosenkranz S.L., Fichtenbaum C.J., et al, for the AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.J Acquir Immune Defic Syndr 2005;39:307—312.
Yu C.Y., Campbell S.E., Sponseller C.A., et al. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig 2014;34:475—482.
Nathan B., Bayley J., Waters L., Post F.A. Cobicistat: a novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther 2013;2:111—122.
Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556—2564.
Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123—1130.
Galescu O., Bhangoo A., Ten S. Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. Rev Endocr Metab Disord 2013;14:133—140.
15.Erlandson K.M., Jiang Y., Debanne S.M., McComsey G.A. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis 2015;61:1566—1572.
Gumprecht J., Gosho M., Budinski D., Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011;13:1047—1055.
Vallejo-Vaz A.J., Kondapally Seshasai S.R., Kurogi K., et al. Effect of pitavastatin therapy on glucose, HbA1c and incident of diabetes mellitus: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015;241:409—418.